News about "Cipla"

Cipla Partners with Qilu to Bring Pembrolizumab Biosimilar to US Market

Cipla and Qilu Pharmaceutical partner to commercialise QL2107, a pembrolizumab biosimilar, in the US, strengthening Cipla’s oncology and biosimilars portfolio.

Cipla | 04/09/2026 | By News Bureau |  100

Cipla Partners with CTTQ to Develop and Commercialise HER2-Targeted ADC in Emerging Markets

Cipla and CTTQ partner to expand access to TQB2102, an investigational HER2 bispecific ADC being evaluated across HER2-expressing cancers.

Cipla | 01/09/2026 | By News Bureau |  107

Cipla's InvaGen Receives US FDA EIR for New York Manufacturing Facility

Cipla's subsidiary InvaGen has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA), marking the successful closure of the inspection at its New York facility.

Cipla | 04/08/2026 | By News Bureau |  137

Cipla Wins US FDA Approval for Generic Advair Diskus

Cipla has received US Food and Drug Administration (FDA) approval for its generic Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in all 3 strengths.

Cipla | 29/07/2026 | By News Bureau |  128

Alembic Pharma Names Ramesh Juneja as EVP, Human Health

Alembic Pharmaceuticals has appointed Ramesh Juneja as Executive Vice President–Human Health for its India business. Bringing leadership experience from Sun Pharma, Cipla and Reliance Retail, Juneja will spearhead sales and marketing initiatives to drive growth in Alembic’s domestic pharmaceutical business.

Cipla | 02/06/2026 | By News Bureau |  183

Pfizer Reaches Three Settlement Deals for VYNDAMAX

Pfizer reaches three settlement agreements for VYNDAMAX, extending US patent exclusivity to June 1, 2031, subject to the outcome of other litigation.

Cipla | 30/04/2026 | By News Bureau |  291

Cipla Launches Saxenda for Weight Management

Cipla has strengthened its US portfolio with the launch of a generic version of Saxenda (liraglutide injection), indicated for chronic weight management. The launch follows ANDA approval from the US Food and Drug Administration (FDA), granted to its partner Orbicular, paving the way for expanded access to a more affordable GLP-1 therapy in the US.

Cipla | 02/03/2026 | By News Bureau |  276

Pfizer and Cipla Form Exclusive Marketing Partnership for Select Brands in India

Pfizer and Cipla have joined forces in an exclusive marketing and distribution agreement for select brands in India. The collaboration aims to improve access and availability of these key medicines, ensuring patients across the country benefit from a wider reach and streamlined supply.

Cipla | 19/12/2025 | By News Bureau |  336

Cipla Partners with Stempeutics, Launches Stem Cell Therapy for Knee Osteoarthritis

Cipla has partnered with Stempeutics to launch Ciplostem, a single-dose stem cell therapy for knee osteoarthritis. The treatment uses 25 million expanded Bone Marrow–derived Mesenchymal Stem Cells (BM-MSCs) combined with hyaluronic acid to support joint repair and pain relief.

Cipla | 04/12/2025 | By Dineshwori |  307

Cipla Launches India's First Dedicated Lung Health Diagnostics Centre in Delhi

Cipla has opened the country’s first dedicated lung diagnostics centre in Delhi, equipped to conduct over 60 tests across respiratory function, microbial studies, immune profiling, blood chemistry and imaging.

Cipla | 29/11/2025 | By Dineshwori |  303